Introduction Transcatheter aortic valve replacement (TAVR) has become the standard
treatment option for patients with symptomatic severe aortic stenosis (AS) with high surgical
risk and a reasonable option for intermediate surgical risk as an alternative to surgical aortic
valve replacement (SAVR). The role of TAVR in lower risk patients is less established but
has been the focus of recent randomized controlled trials (RCTs). We performed a meta-
analysis of RCTs to assess TAVR outcomes among low surgical risk patients. Methods and …